首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1776226

血栓清除裝置:市場洞察·競爭情形·市場預測 (～2032年)

Thrombectomy Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日期: 2025年07月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

預計血栓清除器械市場規模將從2024年的16.5688億美元增長至2032年的28.0685億美元，預測期內複合年增長率為6.83%。

血栓清除器械的需求受多個關鍵因素驅動，支撐了市場的強勁成長。首先，全球神經系統和心血管疾病（例如急性缺血性中風、肺栓塞和深部靜脈血栓形成 (DVT)）的發生率不斷上升，需要快速有效的干預。此外，患者和醫護人員也越來越多地選擇微創治療。領先企業的持續創新和新產品的推出，進一步推動了市場的成長，他們加大對先進技術的投入，以開發能夠提高手術效率和療效的下一代產品。這些趨勢共同為市場在2025年至2032年期間的持續成長奠定了有利基礎。

血栓切除器械：市場動態

根據英國心臟基金會（2024年）的報告，全球約有5600萬女性和4500萬男性中風，這表明腦血管疾病在全球範圍內造成了沉重的負擔。該基金會的另一份報告（截至2022年）也估計，全球冠狀動脈疾病的患病人數將達到約2.5億人，這進一步凸顯了有效幹預措施的必要性。此外，世界中風組織（2023年）的數據估計，四分之一的25歲及以上成年人在其一生中會經歷中風，全球已有超過1.1億人經歷過中風。血栓清除裝置在物理清除阻塞動脈和靜脈的血栓，恢復急性缺血性中風和周邊動脈血栓形成等危及生命的疾病中的血流方面發揮著至關重要的作用。

根據澳洲國家健康研究所 (2022) 的數據，澳洲每年有超過 17,000 人患有靜脈血栓栓塞症 (VTE)。血栓相關疾病的增加進一步凸顯了對血栓清除裝置等有效治療方法的需求。

此外，英國心臟基金會 (2025) 的最新數據估計，到 2024 年，英國將有超過 760 萬人患有心臟病或循環系統疾病，其中包括 400 萬男性和 360 萬名女性。預計到2030年，這一數字將增加100萬，到2040年將再增加200萬，這將推動對治療這些慢性疾病的先進醫療技術的需求，尤其是能夠快速清除血栓並恢復血液流動的設備。

此外，美國心臟協會（2023年）報告稱，週邊動脈疾病（PAD）影響著美國超過1200萬人和全球超過2億人。 PAD病例的快速增長推動了對血栓清除設備的需求，這些設備廣泛用於清除心臟和腦外動脈的阻塞。這些微創設備在恢復血液流動、緩解症狀和改善長期療效方面發揮關鍵作用。

本報告研究了全球血栓清除設備市場，並提供了市場概況、市場影響因素和機會分析、監管環境、市場規模趨勢和預測、按細分市場、地區和主要國家/地區進行的詳細分析、競爭格局以及主要公司的概況。

推動市場要素
- 增長神經系統與心血管疾病
- 微創和非手術治療需求不斷增長
- 主要公司產品開發活動不斷增加
市場限制與課題
- 血栓切除術相關風險與併發症
- 嚴格的監管審批和合規要求
市場機遇
- 機器人手術和人工智慧引導手術等先進技術的發展
- 溶栓藥物與血栓切除器械的整合

第6章血栓清除裝置市場:波特的五力分析

第7章血栓清除裝置市場評估

各產品
- 吸引血栓清除裝置
- 超音波血栓清除裝置
- 其他
各用途
- 末稍血管血栓消除術
- 冠狀動脈血栓消除術
- 神經血管血栓消除術
各終端用戶
- 醫院·診療所
- 門診病人手術中心
地區
- 北美
- 歐洲
- 亞太地區
- 其他地區

第8章血栓清除裝置市場:企業·產品簡介

Stryker
Abbott Laboratories
Boston Scientific Corporation
Argon Medical Devices
Contego Medical, Inc.
Mermaid Medical
Surmodics, Inc.
Penumbra, Inc.
Medtronic
Johnson & Johnson Services, Inc.
Edwards Lifesciences Corporation
Terumo Corporation
Koninklijke Philips N.V.
MicroPort Scientific Corporation
Thrombolex
phenox GmbH
Acandis GmbH
Inova
Vesalio Inc.
ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.

第9章 KOL的見解

第10章計劃方法

第11章關於DelveInsight

第12章詢問免責聲明

簡介目錄圖表

Product Code: DIMDCL0692

Thrombectomy Devices Market by Product (Mechanical Thrombectomy Devices, Aspiration Thrombectomy Devices, Ultrasonic Thrombectomy Devices, and Others), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of neurological and cardiovascular diseases and increasing product development activities among the key market players.

The thrombectomy devices market was valued at USD 1,656.88 million in 2024, growing at a CAGR of 6.83% during the forecast period from 2025 to 2032 to reach USD 2,806.85 million by 2032. The growing demand for thrombectomy devices is driven by several key factors supporting strong market growth. The rising global prevalence of neurological and cardiovascular conditions such as acute ischemic stroke, pulmonary embolism, and deep vein thrombosis, among others necessitate timely, effective interventions. Additionally, there is a clear shift toward minimally invasive treatment options, preferred by both patients and healthcare providers. Further fueling growth in the market is the continuous innovation and product launches by leading players, which are investing in advanced technologies and launching next-generation products that enhance procedural efficiency and outcomes. Collectively, these trends are creating a favorable environment for sustained market expansion from 2025 to 2032.

Thrombectomy Devices Market Dynamics:

According to the British Heart Foundation (2024), an estimated 56 million women and 45 million men worldwide were stroke survivors, reflecting the immense global burden of cerebrovascular disease. The same source also reported that, as of 2022, nearly 250 million people globally were living with coronary heart disease, further emphasizing the need for effective interventional solutions. Similarly, data from the World Stroke Organization (2023), highlighted that one in four adults over the age of 25 would suffer a stroke in their lifetime, and over 110 million individuals worldwide had already experienced one. Thrombectomy devices play a vital role in restoring blood flow by physically removing blood clots that obstruct arteries or veins, especially in acute, life-threatening conditions such as ischemic stroke or peripheral arterial thrombosis.

According to data from the National Institute of Health (2022), over 17,000 individuals in Australia develop venous thromboembolism (VTE) annually. This rising burden of blood clot-related conditions underscores the critical need for effective treatment options like thrombectomy devices.

Recent data from the British Heart Foundation (2025) revealed that, in 2024, more than 7.6 million people in the UK were living with heart and circulatory diseases, including over 4 million men and 3.6 million women with projections indicating that this number was expected to grow by 1 million by 2030, and by 2 million by 2040, highlighting the increasing demand for advanced medical technologies to manage these conditions, particularly devices that can promptly remove dangerous clots and restore blood flow.

Moreover, data from the American Heart Association (2023), reported that more than 12 million Americans, along with 200 million individuals globally, were suffering from peripheral artery disease (PAD). This alarming rise in PAD cases is fueling demand for thrombectomy devices, which are widely used to clear blockages in arteries outside the heart and brain. These minimally invasive devices play a crucial role in restoring circulation, alleviating symptoms, and improving long-term patient outcomes.

Further, key market players are intensifying their R&D efforts to develop and commercialize next-generation thrombectomy systems. For instance, in March 2025, Inari Medical (part of Stryker) launched the Artix(TM) Thrombectomy System, an integrated platform combining aspiration and mechanical thrombectomy for peripheral arterial disease. This next-generation device offers enhanced procedural control and versatility, expanding treatment options for patients with arterial thromboembolic conditions.

In April 2024, AngioDynamics received FDA clearance for its AlphaVac F1885 System to treat pulmonary embolism (PE), expanding its use beyond general thrombectomy. This minimally invasive device offers a mechanical solution for removing blood clots, improving clinical outcomes and safety for PE patients. The clearance, supported by strong clinical trial results, is expected to drive market growth by broadening treatment options and enhancing procedural efficiency.

However, the risk and complications associated with thrombectomy procedures and the strict regulatory approvals and compliance requirements, among others are some of the key constraints that may limit the growth of the thrombectomy devices market.

Thrombectomy Devices Market Segment Analysis:

In the product segment of the thrombectomy devices market, the mechanical thrombectomy devices category is estimated to account for the largest market share in 2024. This can be primarily attributed to the rising prevalence of cardiovascular disorders (CVDs) such as strokes. Additionally, various advantages and applications provided by these devices could also raise the demand for the category.

A major factor driving this segment is the rising global prevalence of peripheral vascular and thrombotic disorders, such as peripheral artery disease (PAD), stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). According to the British Heart Foundation (2024), over 110 million individuals were affected by peripheral arterial (vascular) disease, while 94 million people globally were living with the effects of stroke. Similarly, the Global Stroke Factsheet (2022), stated that the risk of developing a stroke has increased by 50% over the last 17 years and now 1 in 4 people is estimated to have a stroke in their lifetime. According to the same source, globally 101 million people were suffering from stroke. Thus, the increasing prevalence of CVDs will create a need for the treatment of such disorders leading to the increasing demand for mechanical thrombectomy devices. These figures highlight the urgent need for effective clot-removal solutions often performed by mechanical thrombectomy devices.

One of the key clinical benefits of mechanical thrombectomy is its ability to rapidly restore blood flow, a feature that is especially crucial in life-threatening conditions such as acute ischemic stroke. The minimally invasive design of these devices typically introduced through a small puncture site offers several patient-centric advantages, including shorter hospital stays, quicker return to function, and lower complication rates when compared to open surgery.

Mechanical thrombectomy devices are specialized tools designed to remove blood clots from blood vessels. These devices are primarily used in treating conditions like ischemic stroke, deep vein thrombosis (DVT), and peripheral artery disease. These devices can quickly remove clots, restoring blood flow to affected areas and reducing the risk of long-term damage. In cases of ischemic stroke, this can be crucial in minimizing neurological deficits.

Additionally, by directly targeting and removing the clot, mechanical thrombectomy can reduce the risk of secondary complications like distal embolization (where parts of the clot break off and cause further blockages) and reocclusion (where the vessel becomes blocked again). Further, thrombectomy devices offer precise control over clot removal, which can be particularly advantageous in complex cases where other methods might be less effective or more risky.

Furthermore, various companies are conducting research and development related to thrombectomy devices to increase their product portfolio. For instance, in May 2023, Akura Medical, a Shifamed portfolio company initiated its first-in-human clinical study of the Akura mechanical thrombectomy device. The Akura platform is a low-profile solution designed to easily access and efficiently remove large volume, mixed morphology clots, and eliminate the guesswork around the procedure. Similarly, in April 2025, Surmodics announced the commercial launch of the Pounce(TM) XL Thrombectomy System. This next-generation device was designed for the rapid, non-surgical extraction of acute or chronic clots from the iliac and femoral arteries, eliminating the need for thrombolytic drugs. Such advancements address the critical need for safer, more efficient clot removal options, particularly for patients who are not suitable for thrombolytic therapy.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of thrombectomy devices across the globe.

North America is expected to dominate the overall thrombectomy devices market:

North America is expected to hold the largest share of the thrombectomy devices market in 2024, driven by several key factors. The region's dominance can be attributed to the high prevalence of neurovascular, peripheral, and coronary vascular diseases, the rapidly growing geriatric population, and the continuous innovation and product launches by leading medical device companies based in the region. These elements, combined with advanced healthcare infrastructure, favorable reimbursement policies, and increasing awareness of minimally invasive procedures, are expected to sustain North America's leading position in the global market.

According to data from the Centers for Disease Control and Prevention (2024), over 795,000 individuals in the United States experience a stroke each year. Notably, nearly 185,000 of these strokes, accounting for approximately 1 in 4 cases occur in individuals with a history of prior strokes. Additionally, the CDC reported that approximately 900,000 people in the U.S. were affected by venous thromboembolism (VTE) annually, further underlining the substantial burden of thromboembolic diseases. These increasing figures highlighted the growing need for thrombectomy devices, which are designed to physically remove blood clots and restore normal circulation in affected vessels thereby escalating the overall market across the region.

The prevalence of coronary heart disease (CHD) is also a major driver of market growth. According to CDC data from June 2024, around 20.5 million Americans were living with CHD as of 2022. Furthermore, an estimated 6.5 million individuals aged 40 and older were diagnosed with peripheral artery disease (PAD) in the same year. These increasing figures highlight the growing need for thrombectomy devices, which are designed to physically remove blood clots and restore normal circulation in affected vessels.

In addition to rising disease prevalence, North America market is also benefiting from technological innovation and new product launches. For instance, in September 2024, Vesalio announced the U.S. commercialization of the pVasc(TM) Thrombectomy System, a device designed for the non-surgical removal of peripheral occlusions. The pVasc(TM) system targets a wide range of emboli, from soft, acute clots to fibrin-rich, calcified ones, providing a fast, safe, and versatile treatment option. Such developments not only enhance treatment efficacy but also expand the range of conditions that can be managed with thrombectomy devices.

Thrombectomy Devices Market Key Players:

Some of the key market players operating in the thrombectomy devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.

Recent Developmental Activities in the Thrombectomy Devices Market:

In February 2025, Stryker completed the acquisition of Inari Medical, Inc., significantly strengthening its position in the thrombectomy market. Inari's product portfolio, including the FlowTriever(R) System for pulmonary embolism and the ClotTriever(R) System for peripheral vessel thrombectomy, is highly complementary to Stryker's existing Neurovascular business.
In February 2025, the Tendvia(TM) Pulmonary Artery Thrombectomy System from Shanghai Tendfo Medical Device Co., Ltd. received approval from the China National Medical Products Administration (NMPA). The device is indicated for transcatheter thrombectomy in patients with acute high-risk or intermediate-risk pulmonary embolism, offering a minimally invasive treatment option for these critical conditions.
In September 2024, Argon Medical Devices announced the launch of the CLEANER Vac(TM) Thrombectomy System, specifically designed for the removal of blood clots from the peripheral venous vasculature. This disposable, large-bore aspiration system was engineered to quickly and effectively remove thrombus (blood clots) from vessels with restricted blood flow.
In January 2023, phenox Inc. announced that it had received FDA 510(k) clearance for its pRESET(R) Thrombectomy Device for the treatment of acute ischemic stroke. The pRESET(R) device is used as a mechanical thrombectomy solution designed to restore blood flow in patients experiencing acute ischemic stroke.

Key takeaways from the thrombectomy devices market report study

Market size analysis for current thrombectomy devices market size (2024), and market forecast for 8 years (2025 to 2032).
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
Key companies dominating the thrombectomy devices market.
Various opportunities available for the other competitors in the thrombectomy devices market space.
What are the top-performing segments in 2024? How these segments will perform in 2032?
Which are the top-performing regions and countries in the current thrombectomy devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for thrombectomy devices market growth in the coming future?

Target audience who can benefit from this thrombectomy devices market report study

Thrombectomy device product providers
Research organizations and consulting companies
Thrombectomy devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in thrombectomy devices
Various end-users who want to know more about the thrombectomy devices market and the latest technological developments in the thrombectomy devices market.

Frequently Asked Questions for the Thrombectomy Devices Market:

1. What are thrombectomy devices?

Thrombectomy devices are medical devices used to remove blood clots from blood vessels, restoring normal blood flow. They are commonly used in treating conditions like stroke, deep vein thrombosis (DVT), and peripheral artery disease (PAD). These devices can be mechanical, aspiration-based, or combined with thrombolytic therapy for enhanced clot removal.

2. What is the market for thrombectomy devices?

The thrombectomy devices market was valued at USD 1,656.88 million in 2024, growing at a CAGR of 6.83% during the forecast period from 2025 to 2032 to reach USD 2,806.85 million by 2032.

3. What are the drivers for the thrombectomy devices market?

The growing demand for thrombectomy devices is driven by several key factors supporting strong market growth. The rising global prevalence of neurological and cardiovascular conditions such as acute ischemic stroke, pulmonary embolism, and deep vein thrombosis, among others necessitate timely, effective interventions. Additionally, there is a clear shift toward minimally invasive treatment options, preferred by both patients and healthcare providers. Further fueling growth is continuous innovation and product launches by leading players, which are investing in advanced technologies and launching next-generation products that enhance procedural efficiency and outcomes. Collectively, these trends are creating a favorable environment for sustained market expansion from 2025 to 2032.

4. Who are the key players operating in the thrombectomy devices market?

Some of the key market players operating in the thrombectomy devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.

5. Which region has the highest share in the thrombectomy devices market?

North America is expected to hold the largest share of the thrombectomy devices market in 2024, driven by several key factors. The region's dominance can be attributed to the high prevalence of neurovascular, peripheral, and coronary vascular diseases, the rapidly growing geriatric population, and the continuous innovation and product launches by leading medical device companies based in the region. These elements, combined with advanced healthcare infrastructure, favorable reimbursement policies, and increasing awareness of minimally invasive procedures, are expected to sustain North America's leading position in the global market.

1. Thrombectomy Devices Market Report Introduction

1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption

2. Thrombectomy Devices Market Executive Summary

2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

4.1. The United States
4.2. Europe
4.3. Japan
4.4. China

5. Thrombectomy Devices Market Key Factors Analysis

5.1. Thrombectomy Devices Market Drivers
- 5.1.1. The growing prevalence of neurological and cardiovascular diseases
- 5.1.2. Increasing demand for minimally invasive & non-surgical procedures
- 5.1.3. Increasing product development activities among the key players
5.2. Thrombectomy Devices Market Restraints and Challenges
- 5.2.1. Risk and complications associated with thrombectomy procedures
- 5.2.2. Strict regulatory approvals and compliance requirements
5.3. Thrombectomy Devices Market Opportunity
- 5.3.1. Development of advanced technologies such as robotic surgery, AI-guided surgical procedures, among others
- 5.3.2. Integration of thrombolytic drugs with thrombectomy devices

6. Thrombectomy Devices Market Porter's Five Forces Analysis

6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. Thrombectomy Devices Market Assessment

7.1. By Product
- 7.1.1. Thrombectomy Devices
- 7.1.2. Aspiration Thrombectomy Devices
- 7.1.3. Ultrasonic Thrombectomy Devices
- 7.1.4. Others
7.2. By Application
- 7.2.1. Peripheral Vascular Thrombectomy
- 7.2.2. Coronary Vascular Thrombectomy
- 7.2.3. Neurovascular Thrombectomy
7.3. By End-User
- 7.3.1. Hospitals & Clinics
- 7.3.2. Ambulatory Surgical Centers
- 7.3.3. Others
7.4. By Geography
- 7.4.1. North America
  - 7.4.1.1. United States Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.1.2. Canada Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.1.3. Mexico Thrombectomy Devices Market Size in USD million (2022-2032)
- 7.4.2. Europe
  - 7.4.2.1. France Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.2.2. Germany Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.2.3. United Kingdom Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.2.4. Italy Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.2.5. Spain Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.2.6. Rest of Europe Thrombectomy Devices Market Size in USD million (2022-2032)
- 7.4.3. Asia-Pacific
  - 7.4.3.1. China Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.3.2. Japan Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.3.3. India Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.3.4. Australia Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.3.5. South Korea Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.3.6. Rest of Asia-Pacific Thrombectomy Devices Market Size in USD million (2022-2032)
- 7.4.4. Rest of the World (RoW)
  - 7.4.4.1. Middle East Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.4.2. Africa Thrombectomy Devices Market Size in USD million (2022-2032)
  - 7.4.4.3. South America Thrombectomy Devices Market Size In USD Million (2022-2032)

8. Thrombectomy Devices Market Company and Product Profiles

8.1. Stryker
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. Abbott Laboratories
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. Boston Scientific Corporation
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. Argon Medical Devices
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. Contego Medical, Inc.
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. Mermaid Medical
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. Surmodics, Inc.
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. Penumbra, Inc.
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. Medtronic
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. Johnson & Johnson Services, Inc.
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. Edwards Lifesciences Corporation
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. Terumo Corporation
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. Koninklijke Philips N.V.
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. MicroPort Scientific Corporation
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. Thrombolex
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. phenox GmbH
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. Acandis GmbH
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. Inova
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. Vesalio Inc.
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy